A Phase I Study of Actinium-225-Labeled HuM195 Antibody in Patients with Advanced Myeloid Malignancies
[Protocol 02-017] |
Douer, Dan, MD |
A Phase I Study of BMS-936558 in Patients with Relapsed or Refractory Hematologic Cancers
[Protocol 12-142] |
Lesokhin, Alexander, MD |
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
[Protocol 13-045] |
Younes, Anas, MD |
A Phase I Study of EPZ-5676 in Patients with Relapsed/Refractory Leukemia and Other Advanced Hematologic Cancers
[Protocol 12-181] |
Tallman, Martin, MD |
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
[Protocol 12-088] |
Horwitz, Steven, MD |
A Phase I Study of Plerixafor as a Chemosensitizing Agent for Children with Relapsed Acute Leukemia or Myelodysplastic Syndromes
[Protocol 11-208] |
Trippett, Tanya, MD |
A Phase I Study of the Treatment of Beta-Thalassemia with a Gene Transfer Approach
[Protocol 10-164] |
Boulad, Farid, MD |
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
[Protocol 07-055] |
O'Reilly, Richard, MD |
A Phase I Study of WT1-Specific Donor-Derived T Cells in Patients with Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia after T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-175] |
Koehne, Guenther, MD, PhD |
A Phase I/II Study of AT7519M with and without Bortezomib in Patients with Previously Treated Multiple Myeloma
[Protocol 10-151] |
Landau, Heather, MD |
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies
[Protocol 06-125] |
Boulad, Farid, MD |
A Phase I/IIA Study of Carfilzomib plus High-Dose Melphalan Before Autologous Stem Cell Transplant in Patients with Multiple Myeloma
[Protocol 12-144] |
Landau, Heather, MD |
A Phase IB Study of SAR650984 with Lenalidomide and Dexamethasone to Treat Recurrent or Persistent Multiple Myeloma
[Protocol 13-006] |
Lendvai, Nikoletta, MD |
A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
[Protocol 10-174] |
Gerecitano, John, MD, PhD |
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
[Protocol 12-170] |
Horwitz, Steven, MD |
A Phase II Study of AUY922 in Patients with Myelofibrosis
[Protocol 12-076] |
Rampal, Raajit, MD |
A Phase II Study of Bendamustine and Dexamethasone in Patients with Relapsed Amyloidosis
[Protocol 12-257] |
Landau, Heather, MD |
A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 12-016] |
Giralt, Sergio, MD |
A Phase II Study of Lenalidomide Intensification in Patients with Asymptomatic Multiple Myeloma that Has Progressed with Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation
[Protocol 11-107] |
Hassoun, Hani, MD |
A Phase II Study of Palifermin with or without Leuprolide After T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-077] |
Goldberg, Jenna, MD |
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS
[Protocol 08-008] |
Castro-Malaspina, Hugo, MD |
A Phase II Study of Pomalidomide plus Autologous Stem Cell Transplantation versus Pomalidomide/Dexamethasone in Patients with Multiple Myeloma
[Protocol 12-138] |
Giralt, Sergio, MD |
A Phase II Study of Siltuximab in Patients with High-Risk Smoldering Multiple Myeloma
[Protocol 12-068] |
Lesokhin, Alexander, MD |
A Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
[Protocol 12-131] |
Hyman, David, MD |
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia
[Protocol 08-031] |
Boulad, Farid, MD |
A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
[Protocol 07-035] |
Hsu, Katharine, MD, PhD |
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050] |
O'Reilly, Richard, MD |
A Phase III Study of Lenalidomide Alone and in Combination with Epoetin Alfa in Patients with Myelodysplastic Syndromes and Symptomatic Anemia
[Protocol 10-128] |
Klimek, Virginia, MD |
A Phase III Study of Lenalidomide, Bortezomib, and Dexamethasone Combination Treatment with or without Peripheral Stem Cell Transplantation in the Initial Management of Multiple Myeloma
[Protocol 12-018] |
Hassoun, Hani, MD |
A Pilot Study of Acupuncture to Control Symptoms in Patients Receiving Stem Cell Transplantation for Multiple Myeloma
[Protocol 13-038] |
Deng, Gary, MD, PhD |
A Pilot Study of Bortezomib/Dexamethasone Followed by Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone for the Initial Treatment of MIDD Associated with Multiple Myeloma and Amyloidosis
[Protocol 11-061] |
Hassoun, Hani, MD |
A Pilot Study of MAGE-A3 Vaccination as Consolidation Therapy for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
[Protocol 10-216] |
Lendvai, Nikoletta, MD |
A Pilot Study of the Wilms' Tumor 1 (WT1) Analog Peptide Vaccine in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation
[Protocol 12-288] |
Koehne, Guenther, MD, PhD |
A Pilot Trial of Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
[Protocol 11-105] |
Landau, Heather, MD |
A Prospective Natural History Study of the Diagnosis, Treatment, and Outcomes of Children with SCID Disorders
[Protocol 10-150] |
O'Reilly, Richard, MD |
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
[Protocol 08-087] |
Barker, Juliet, MBBS |
A Study of Allogeneic Stem Cell Transplantation in HIV-Infected Patients with Hematologic Cancers
[Protocol 12-092] |
Sauter, Craig, MD |
A Study of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post-Transplantation Donor Lymphocyte Infusions for Patients with Relapsed or High-Risk Multiple Myeloma
[Protocol 10-051] |
Koehne, Guenther, MD, PhD |
A Study of Posaconazole Versus Micafungin to Protect Against Invasive Fungal Infections in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome
[Protocol 10-038] |
Papanicolaou, Genovefa, MD |
A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
[Protocol 09-171] |
Landau, Heather, MD |
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLA-Compatible Donor
[Protocol 12-053] |
O'Reilly, Richard, MD |
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy
[Protocol 06-014] |
Barker, Juliet, MBBS |
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation from HLA-Compatible Unrelated Donors in Severe Aplastic Anemia
[Protocol 06-056] |
Castro-Malaspina, Hugo, MD |
Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Cancer and Bone Marrow Transplantation Patients
[Protocol 03-123] |
Meyers, Paul, MD |
Transplantation of Unrelated Donor Double-Unit Cord Blood with T-Cell-Depleted Stem Cells for Patients with High-Risk Hematologic Cancers
[Protocol 12-153] |
Barker, Juliet, MBBS |
